179 related articles for article (PubMed ID: 37137346)
21. Epstein-Barr virus (EBV) and human disease: facts, opinions and problems.
Griffin BE
Mutat Res; 2000 Apr; 462(2-3):395-405. PubMed ID: 11523539
[TBL] [Abstract][Full Text] [Related]
22. Epstein-Barr virus latent membrane protein-1 oncogene deletions: correlations with malignancy in Epstein-Barr virus--associated lymphoproliferative disorders and malignant lymphomas.
Kingma DW; Weiss WB; Jaffe ES; Kumar S; Frekko K; Raffeld M
Blood; 1996 Jul; 88(1):242-51. PubMed ID: 8704180
[TBL] [Abstract][Full Text] [Related]
23. Molecular detection of Epstein-Barr virus in different types of lymphoma.
Shaklawoon K; Altagazi N; Altorjman F; Alturki A; Eltaweel M; Alqawi O
Mol Biol Rep; 2020 Mar; 47(3):1803-1807. PubMed ID: 31993862
[TBL] [Abstract][Full Text] [Related]
24. Epstein-Barr virus latent membrane protein-1 activates CD25 expression in lymphoma cells involving the NFkappaB pathway.
Vockerodt M; Tesch H; Kube D
Genes Immun; 2001 Dec; 2(8):433-41. PubMed ID: 11781710
[TBL] [Abstract][Full Text] [Related]
25. Restricted low-level human antibody responses against Epstein-Barr virus (EBV)-encoded latent membrane protein 1 in a subgroup of patients with EBV-associated diseases.
Meij P; Vervoort MB; Aarbiou J; van Dissel P; Brink A; Bloemena E; Meijer CJ; Middeldorp JM
J Infect Dis; 1999 May; 179(5):1108-15. PubMed ID: 10191211
[TBL] [Abstract][Full Text] [Related]
26. Rapamycin reverses splenomegaly and inhibits tumor development in a transgenic model of Epstein-Barr virus-related Burkitt's lymphoma.
Cen O; Longnecker R
Mol Cancer Ther; 2011 Apr; 10(4):679-86. PubMed ID: 21282357
[TBL] [Abstract][Full Text] [Related]
27. CpG methylation of the major Epstein-Barr virus latency promoter in Burkitt's lymphoma and Hodgkin's disease.
Robertson KD; Manns A; Swinnen LJ; Zong JC; Gulley ML; Ambinder RF
Blood; 1996 Oct; 88(8):3129-36. PubMed ID: 8874213
[TBL] [Abstract][Full Text] [Related]
28. Acute or chronic life-threatening diseases associated with Epstein-Barr virus infection.
Okano M; Gross TG
Am J Med Sci; 2012 Jun; 343(6):483-9. PubMed ID: 22104426
[TBL] [Abstract][Full Text] [Related]
29. Epstein-Barr Virus MicroRNA miR-BART5-3p Inhibits p53 Expression.
Zheng X; Wang J; Wei L; Peng Q; Gao Y; Fu Y; Lu Y; Qin Z; Zhang X; Lu J; Ou C; Li Z; Zhang X; Liu P; Xiong W; Li G; Yan Q; Ma J
J Virol; 2018 Dec; 92(23):. PubMed ID: 30209170
[TBL] [Abstract][Full Text] [Related]
30. Epstein-Barr virus: the first human tumor virus and its role in cancer.
Pagano JS
Proc Assoc Am Physicians; 1999; 111(6):573-80. PubMed ID: 10591086
[TBL] [Abstract][Full Text] [Related]
31. Natural Killer cell transcriptome during primary EBV infection and EBV associated Hodgkin Lymphoma in children-A preliminary observation.
M A; Chatterjee S; A P; S M; Davuluri S; Ar AK; T A; M P; Cs P; Sinha M; Chugani A; R VP; Kk A; R S J
Immunobiology; 2020 May; 225(3):151907. PubMed ID: 32044149
[TBL] [Abstract][Full Text] [Related]
32. Epstein-Barr virus and nasopharyngeal carcinoma.
Young LS; Dawson CW
Chin J Cancer; 2014 Dec; 33(12):581-90. PubMed ID: 25418193
[TBL] [Abstract][Full Text] [Related]
33. Resveratrol inhibits proliferation and survival of Epstein Barr virus-infected Burkitt's lymphoma cells depending on viral latency program.
De Leo A; Arena G; Stecca C; Raciti M; Mattia E
Mol Cancer Res; 2011 Oct; 9(10):1346-55. PubMed ID: 21856773
[TBL] [Abstract][Full Text] [Related]
34. Analysis of SH2D1A mutations in patients with severe Epstein-Barr virus infections, Burkitt's lymphoma, and Hodgkin's lymphoma.
Parolini O; Kagerbauer B; Simonitsch-Klupp I; Ambros P; Jaeger U; Mann G; Haas OA; Morra M; Gadner H; Terhorst C; Knapp W; Holter W
Ann Hematol; 2002 Aug; 81(8):441-7. PubMed ID: 12224001
[TBL] [Abstract][Full Text] [Related]
35. Epstein-Barr virus encoded BALF1 gene is transcribed in Burkitt's lymphoma cell lines and in nasopharyngeal carcinoma's biopsies.
Cabras G; Decaussin G; Zeng Y; Djennaoui D; Melouli H; Broully P; Bouguermouh AM; Ooka T
J Clin Virol; 2005 Sep; 34(1):26-34. PubMed ID: 16087121
[TBL] [Abstract][Full Text] [Related]
36. Epstein-Barr virus viral load and serology in childhood non-Hodgkin's lymphoma and chronic inflammatory conditions in Uganda: implications for disease risk and characteristics.
Orem J; Sandin S; Mbidde E; Mangen FW; Middeldorp J; Weiderpass E
J Med Virol; 2014 Oct; 86(10):1796-803. PubMed ID: 24889739
[TBL] [Abstract][Full Text] [Related]
37. STRUCTURAL AND FUNCTIONAL CHARACT ERISTICS OF THE LMP1 ONCOGENE IN PATIENTS WITH TUMORS ASSOCIATED AND NOT ASSOCIATED WITH THE EPSTEIN-BARR VIRUS.
Senyuta NB; Smirnova KV; Diduk SV; Goncharova EV; Shcherbak LN; Gurtsevitch VE
Mol Gen Mikrobiol Virusol; 2016 Sep; 34(2):71-75. PubMed ID: 30380210
[TBL] [Abstract][Full Text] [Related]
38. Dynamics of Epstein-Barr virus DNA levels in serum during EBV-associated disease.
Berger C; Day P; Meier G; Zingg W; Bossart W; Nadal D
J Med Virol; 2001 Aug; 64(4):505-12. PubMed ID: 11468736
[TBL] [Abstract][Full Text] [Related]
39. Transcriptional analysis of Epstein-Barr virus gene expression in EBV-positive gastric carcinoma: unique viral latency in the tumour cells.
Sugiura M; Imai S; Tokunaga M; Koizumi S; Uchizawa M; Okamoto K; Osato T
Br J Cancer; 1996 Aug; 74(4):625-31. PubMed ID: 8761381
[TBL] [Abstract][Full Text] [Related]
40. Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence?
Longnecker R
Adv Cancer Res; 2000; 79():175-200. PubMed ID: 10818681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
